MCID: LMB062
MIFTS: 55

Limb Ischemia

Categories: Cardiovascular diseases

Aliases & Classifications for Limb Ischemia

MalaCards integrated aliases for Limb Ischemia:

Name: Limb Ischemia 12 15 37 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050852
UMLS 71 C2945695

Summaries for Limb Ischemia

Disease Ontology : 12 An ischemia that is characterized by low blood supply to tissues in the limb due to interruption in the arterial blood supply.

MalaCards based summary : Limb Ischemia is related to peripheral vascular disease and ischemia. An important gene associated with Limb Ischemia is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include Limb and Bone, and related phenotypes are cardiovascular system and cellular

Related Diseases for Limb Ischemia

Diseases related to Limb Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 583)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 31.7 VWF VEGFA SELE NOS3 IL6 ACE
2 ischemia 31.6 VEGFA TEK NOS3 KDR HIF1A FGF2
3 buerger disease 31.5 SELE NOS3 HGF
4 arteriosclerosis obliterans 31.4 MMP9 IL6 HGF
5 vasculitis 31.0 VWF TNF SELE IL6 CCL2
6 aortic aneurysm, familial abdominal, 1 30.9 MMP9 IL6 CCL2 ACE
7 polyarteritis nodosa 30.9 SELE IL6 FGF2
8 osteomyelitis 30.8 TNF IL6 CCL2
9 intermittent claudication 30.8 VWF VEGFA TEK PGF IL6 ANGPT2
10 lipid metabolism disorder 30.8 SELE IL6 CCL2 ACE
11 antiphospholipid syndrome 30.7 VWF TNF SELE PGF
12 cerebrovascular disease 30.6 VWF TNF SELE MMP9 IL6 ACE
13 peripheral artery disease 30.6 VWF VEGFA TNF NOS3 IL6 HGF
14 chronic ulcer of skin 30.6 VEGFA TNF IL6 FGF2
15 respiratory failure 30.6 TNF IL6 EDN1 ANGPT2 ACE
16 systemic scleroderma 30.5 TNF SELE IL6 EDN1 ACE
17 purpura 30.5 VWF TNF IL6 ACE
18 homocysteinemia 30.5 VWF NOS3 CCL2
19 peripheral nervous system disease 30.5 VEGFA TNF IL6 CCL2 ACE
20 proteasome-associated autoinflammatory syndrome 1 30.5 TNF SELE MMP9 IL6 CCL2
21 collagen disease 30.4 VWF TNF IL6 EDN1 ACE
22 congestive heart failure 30.4 VEGFA TNF NOS3 IL6 EDN1 ANGPT2
23 pulmonary edema 30.4 TNF TEK NOS3 HGF EDN1 ACE
24 angina pectoris 30.4 NOS3 IL6 EDN1 ACE
25 peripartum cardiomyopathy 30.4 VEGFA PGF ACE
26 uremia 30.4 VWF TNF IL6 ACE
27 essential thrombocythemia 30.4 VWF VEGFA TNF IL6 FGF2
28 chronic kidney disease 30.4 VEGFA TNF NOS3 IL6 HGF EDN1
29 plague 30.4 TNF SELE IL6
30 renovascular hypertension 30.4 NOS3 EDN1 ACE
31 infective endocarditis 30.3 TNF SIGLEC5 IL6
32 atrial fibrillation 30.3 VWF NOS3 IL6 ACE
33 intermediate coronary syndrome 30.3 VWF IL6 ACE
34 disseminated intravascular coagulation 30.3 VWF TNF SELE IL6
35 exanthem 30.2 VEGFA TNF KDR IL6 ACE
36 acute cystitis 30.2 TNF IL6 CCL2 ACE
37 nervous system disease 30.2 VEGFA TNF MMP9 IL6
38 coronary heart disease 1 30.2 VWF SELE NOS3 IL6 EDN1 ACE
39 pyoderma 30.2 TNF SIGLEC5 MMP9
40 pyoderma gangrenosum 30.2 TNF SIGLEC5 MMP9
41 sarcoma 30.2 VEGFA KDR IL6 HIF1A FGF2 ANGPT2
42 diabetic angiopathy 30.1 VWF SELE NOS3 EDN1 CCL2
43 carpal tunnel syndrome 30.1 VEGFA IL6 FGF2 CCL2 ACE
44 thrombocytopenia 30.1 VWF TNF SELE IL6 CXCL12 CCL2
45 leukemia, acute myeloid 30.1 VEGFA TNF SIGLEC5 KDR IL6 FGF2
46 decubitus ulcer 30.1 VEGFA TNF MMP9 IL6 FGF2
47 vascular disease 30.0 VWF VEGFA TNF SELE NOS3 MMP9
48 kidney disease 30.0 VWF VEGFA TNF NOS3 IL6 HGF
49 kawasaki disease 30.0 TNF SELE MMP9 IL6 CCL2
50 carotid artery disease 30.0 SELE MMP9 CCL2 ACE

Graphical network of the top 20 diseases related to Limb Ischemia:



Diseases related to Limb Ischemia

Symptoms & Phenotypes for Limb Ischemia

MGI Mouse Phenotypes related to Limb Ischemia:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 ACE ANGPT2 CXCL12 EDN1 FGF2 HGF
2 cellular MP:0005384 10.36 ANGPT2 CXCL12 FGF2 HGF HIF1A IL6
3 homeostasis/metabolism MP:0005376 10.35 ACE ANGPT2 EDN1 FGF2 HIF1A IL6
4 hematopoietic system MP:0005397 10.34 ACE CXCL12 FGF2 HGF HIF1A IL6
5 growth/size/body region MP:0005378 10.32 ACE EDN1 HGF HIF1A IL6 KDR
6 immune system MP:0005387 10.3 ACE ANGPT2 CCL2 CXCL12 HIF1A IL6
7 mortality/aging MP:0010768 10.27 ACE ANGPT2 CXCL12 EDN1 FGF2 HGF
8 digestive/alimentary MP:0005381 10.19 ANGPT2 EDN1 HIF1A IL6 MMP9 NOS3
9 embryo MP:0005380 10.18 ACE EDN1 HGF HIF1A KDR PGF
10 liver/biliary system MP:0005370 10.1 ACE CXCL12 HGF HIF1A IL6 KDR
11 integument MP:0010771 10.09 ANGPT2 HIF1A IL6 KDR MMP9 PGF
12 muscle MP:0005369 10.06 CXCL12 EDN1 FGF2 HIF1A IL6 KDR
13 nervous system MP:0003631 9.93 CXCL12 EDN1 FGF2 HIF1A IL6 KDR
14 neoplasm MP:0002006 9.86 ACE FGF2 HIF1A IL6 MMP9 PGF
15 respiratory system MP:0005388 9.65 ANGPT2 HIF1A IL6 KDR MMP9 NOS3
16 vision/eye MP:0005391 9.4 ANGPT2 FGF2 HIF1A IL6 KDR MMP9

Drugs & Therapeutics for Limb Ischemia

Drugs for Limb Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
6
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
7
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
8
carbamide peroxide Approved Phase 4 124-43-6
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Glucagon Approved Phase 4 16941-32-5
11
Apixaban Approved Phase 4 503612-47-3 10182969
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
14
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
15
Ticagrelor Approved Phase 4 274693-27-5 9871419
16
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
17
tannic acid Approved Phase 4 1401-55-4
18
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
19
Metformin Approved Phase 4 657-24-9 14219 4091
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Adenosine Approved, Investigational Phase 4 58-61-7 60961
22
Insulin glargine Approved Phase 4 160337-95-1
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
24
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
25
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
26 Blood Substitutes Phase 4
27 Antiemetics Phase 4
28 Gastrointestinal Agents Phase 4
29 BB 1101 Phase 4
30 Dexamethasone 21-phosphate Phase 4
31 Antineoplastic Agents, Hormonal Phase 4
32 glucocorticoids Phase 4
33 Vitamins Phase 4
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
35 Anticholesteremic Agents Phase 4
36 Hypolipidemic Agents Phase 4
37 Vitamin B3 Phase 4
38 Vitamin B Complex Phase 4
39 Vitamin B9 Phase 4
40 Folate Phase 4
41 Lipid Regulating Agents Phase 4
42 Nicotinic Acids Phase 4
43 Antimetabolites Phase 4
44 Nutrients Phase 4
45 Trace Elements Phase 4
46 Micronutrients Phase 4
47 Adrenergic Antagonists Phase 4
48 Adrenergic beta-1 Receptor Antagonists Phase 4
49 Adrenergic beta-Antagonists Phase 4
50 Adrenergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 483)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Unknown status NCT02563535 Phase 4
2 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
3 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
4 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
5 The Prism Trial: A Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery Unknown status NCT02085551 Phase 4
6 The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions Unknown status NCT01147419 Phase 4
7 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
8 Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study Completed NCT01558505 Phase 4
9 CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5). Completed NCT00459888 Phase 4
10 EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months. Completed NCT00906022 Phase 4
11 International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease Completed NCT02369809 Phase 4 Neovasculgen®
12 NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions Completed NCT01783600 Phase 4
13 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
14 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
15 Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV) Completed NCT00596752 Phase 4 Alprostadil
16 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
17 Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
18 Balloon Angioplasty Versus Stenting With Nitinol Stents in the Superficial Femoral Artery Completed NCT00281060 Phase 4
19 Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery Completed NCT00190307 Phase 4 aspirin 75 mg/day
20 Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans Completed NCT02117206 Phase 4 L-arginine (L-arginine Veyron);Nacl
21 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
22 Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) Recruiting NCT02829151 Phase 4 Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) );Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel;Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
23 Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With Lower Extremity Peripheral Artery Disease Recruiting NCT04083755 Phase 4 Ferric Carboxymaltose Injection [Injectafer]
24 Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial Recruiting NCT03549923 Phase 4 Esmolol;Standard care
25 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Active, not recruiting NCT01952457 Phase 4
26 Liraglutide Efficacy and Action on Type 2 Diabetes With Peripheral Atherosclerotic intErmittent Claudication (LEADPACE STUDY): a Prospective, 24-week, Multicenter, Randomized, Controlled Clinical Study Not yet recruiting NCT04146155 Phase 4 Liraglutide+standard-of-care treatment
27 Randomized Controlled Trial of Extended-Duration Low-Dose Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Not yet recruiting NCT04168203 Phase 4 Apixaban 2.5 MG;Placebo oral tablet
28 Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia Terminated NCT00504088 Phase 4
29 Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study Terminated NCT00403780 Phase 4 pregabalin;placebo
30 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
31 Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR) Terminated NCT02374957 Phase 4 Cilostazol
32 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Terminated NCT01901224 Phase 4 Metformin 1000 mg;Placebo
33 Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography Terminated NCT02407314 Phase 4 Aspirin;Aspirin + Ticagrelor
34 Effect of Normalization of Fasting Glucose by Intensified Insulin Therapy on the Incidence of Restenosis After Peripheral Angioplasty in Patients With Type 2 Diabetes. Terminated NCT01150617 Phase 4 Insulin glargine plus insulin analogues
35 A Double-blind, Randomized, Parallel Design Two Center Study to Compare the Effect of Vorapaxar vs. Placebo on Lower Extremity Vein Graft Maturation, Remodeling, and Function Withdrawn NCT02975583 Phase 4 Vorapaxar;Placebos
36 Evaluation of Ranolazine on Skeletal Muscle Endpoints During Exercise In Subjects With Chronic Angina and Peripheral Arterial Disease Withdrawn NCT00657514 Phase 4 Ranolazine;Placebo
37 Proteomics and Stem Cell Therapy as a New Vascularization Strategy Withdrawn NCT02408991 Phase 4 Neupogen
38 Stem Cells In Wound Healing With Collagen Matrix as a Carrier Withdrawn NCT02314416 Phase 4
39 Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients: A Randomized Control Trial Withdrawn NCT00390247 Phase 4 thalidomide
40 A Randomized, Controlled Trial of Autologous Platelet Gel Treatment in Diabetic Foot Ulcers Withdrawn NCT00338702 Phase 4
41 Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb Unknown status NCT01211925 Phase 2, Phase 3 Aspirin
42 Study of Parameters of Infracyanine Angiography as Diagnostic Tool of Critical Limb Ischemia Unknown status NCT02820467 Phase 3
43 Prospektive, Randomisierte Und Kontrollierte Studie Zum Einfluss Des VADOplex-Systems Auf Die Lebensqualität im Rahmen Der Behandlung Der Chronisch-kritischen Extremitätenischämie im Stadium IV Nach Fontaine Unknown status NCT02034539 Phase 2, Phase 3
44 Safety and Effectiveness of the SurgWerksTM-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-Reconstructable Critical Limb Ischemia Patients Unknown status NCT02538978 Phase 3
45 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients Unknown status NCT00539266 Phase 2, Phase 3
46 Security and Effectiveness of Autologous Bone Marrow Stem Cell Transplantation to Avoid Amputations in Patients With Limb-threatening Ischemia: A Multicentric Randomized Placebo-controlled Double-blind Study Unknown status NCT00434616 Phase 2, Phase 3
47 Paclitaxel Eluting Stent in Long Superficial Femoral Artery Obstruction: a Prospective, Randomized Comparison With Bypass Surgery Using PTFE Graft in a Finnish Multicenter Study Unknown status NCT01450722 Phase 3
48 Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells Completed NCT01833585 Phase 3
49 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization Completed NCT01483898 Phase 3
50 Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease Completed NCT01245335 Phase 3

Search NIH Clinical Center for Limb Ischemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Limb Ischemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Limb Ischemia:
Enriched bone marrow-derived progenitor cells for ischemic diseases
Alecmestencel-T, mesenchymal stem cells for ischemic diseases
PLX-PAD, placental-derived mesenchymal-like stromal cells for peripheral artery disease
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
ACT34-CLI, bone marrow-derived cells for critical limb ischemia
ReN009, human neural stem cells for peripheral arterial disease
Autologous CD133+ cells for treatment of critical limb ischemia
Bone marrow-derived mononuclear cells for critical limb ischemia
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of peripheral vascular diseases
BMAC, autologous bone marrow aspirate concentrate for critical limb ischemia
Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
ALD-301, bone marrow-derived cells for critical limb ischemia
Bone marrow-derived stem cells for treatment of critical limb ischemia and diabetic foot ulcer
Peripheral blood-derived hematopoietic stem cells for leg gangrene
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesendo, stem cell combination for treatment of limb ischemia
Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
Autologus endothelial progenitor cells for the treatment of critical limb ischemia
Umbilical cord blood stem cells for treatment of critical limb ischemia
PDA002, Placenta-derived cells for vascular disease
Ixmyelocel-T, mesenchymal stem cells and myocytes for critical limb ischemia
ERCs, endometrial regenerative cells for critical limb ischemia
Bone marrow-derived mononuclear cells for peripheral vascular disease
Angiocell, bone marrow-derived stem cells for treatment of critical limb ischemia
ACP-01, autologous angiogenic precursor cells for critical limb ischemia
Bone marrow-derived stem cells for treatment of diabetic foot ulcers
ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
ACY001, bone marrow-derived hematopoietic stem cells for treatment of critical limb ischemia
StempeucelCLI, mesenchymal stem cells for vascular diseases
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
Autologous endothelial progenitor cells for the treatment of critical limb ischemia
Embryonic/Adult Cultured Cells Related to Limb Ischemia:
Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 22163120 23192920 9020076
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
Cord blood-derived hematopoietic stem cell PMIDs: 19558779
Peripheral blood-derived endothelial cells PMIDs: 18388019 19448678
Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 15995108 18351022 19896796 22019148 19500466
Bone marrow-derived mononuclear cells (family) PMIDs: 17394441 23586040 21216483
Tissue repair cells PMIDs: 17394441 23586040
Bone marrow-derived mesenchymal stem cells PMIDs: 21216483
Endometrial regenerative cells PMIDs: 18005405 18713449 19232091
Bone marrow-derived mesenchymal stem cells and monocytes (Ixmyelocel-T) PMIDs: 22453769 22776246 21684715
Bone marrow-derived mononuclear cells PMIDs: 21586448
Bone marrow-derived mesenchymal stem cells PMIDs: 21586448
Placenta-derived adherent stromal cell (PLX) PMIDs: 18154467 19526389 19478280
Neural stem cell line (CTX0E03) PMIDs: 23067568
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 23307180 18720444 22731756
Genetically modified vein-derived smooth muscle
Umbilical cord blood-derived hematopoietic stem cells (family)
Peripheral blood-derived hematopoietic stem cells
Genetically modified vein-derived endothelial cells
Peripheral blood-derived endothelial progenitor cells (family)
Bone marrow-derived mesenchymal stem cells (family)
MultiGeneAngio, transduced vein-derived endothelial cells
Bone marrow-derived mononuclear cells
Peripheral blood-derived hematopoietic stem cells (family)
Placenta-derived cells
Angiogenic cell precursors
MultiGeneAngio, transduced vein-derived smooth muscle cells
Bone marrow-derived mononuclear cells
Bone marrow-derived progenitor cells

Genetic Tests for Limb Ischemia

Anatomical Context for Limb Ischemia

MalaCards organs/tissues related to Limb Ischemia:

40
Bone, Endothelial, Bone Marrow, Heart, Kidney, Skeletal Muscle, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Limb Ischemia:
# Tissue Anatomical CompartmentCell Relevance
1 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
2 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
3 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Limb Ischemia

Articles related to Limb Ischemia:

(show top 50) (show all 7100)
# Title Authors PMID Year
1
Prostanoids for Critical Limb Ischemia: A Clinical Review and Consideration of Current Guideline Recommendations. 61
31769315 2020
2
SPECT/CT Imaging: A Noninvasive Approach for Evaluating Serial Changes in Angiosome Foot Perfusion in Critical Limb Ischemia. 61
31993252 2020
3
Cost-Effectiveness of Drug-Eluting Stents for Infrapopliteal Lesions in Patients with Critical Limb Ischemia: The PADI Trial. 61
31807849 2020
4
Edaravone attenuates lung injury in a hind limb ischemia-reperfusion rat model: A histological, immunohistochemical and biochemical study. 61
31678401 2020
5
Reperfusion Injury with Compartment Syndrome Following Systemic Thrombolysis for Cardiac Catheterization-Related Arterial Thrombosis in an Infant. 61
31984163 2020
6
Therapeutic Window of Clopidogrel and Ticagrelor in Patients With Critical Limb-Threatening Ischemia. 61
31550912 2020
7
Antithrombotic therapy for postinterventional management of peripheral arterial disease. 61
31930282 2020
8
The Geriatric Nutritional Risk Index Predicts Long-Term Survival and Cardiovascular or Limb Events in Peripheral Arterial Disease. 61
31217396 2020
9
Stent crush: A novel endovascular approach for treatment of complex in-stent femoropopliteal chronic total occlusion. 61
31313483 2020
10
Clinical significance of mirror lesions in lower extremity arterial disease. 61
31639273 2020
11
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage after Infrapopliteal Interventions for Critical Limb Ischemia. 61
31626938 2020
12
Using the epidemiology of critical limb ischemia to estimate the number of patients amenable to endovascular therapy. 61
31621531 2020
13
Factors Influencing in-Stent Occlusion after Femoropopliteal Artery Stent Placement with Intravascular Ultrasound Evaluation. 61
31883937 2020
14
Association of comorbid depression with inpatient outcomes in critical limb ischemia. 61
31713461 2020
15
Arterial reconstruction for patients with chronic limb ischemia improves ambulatory function and health related quality of life. 61
32035265 2020
16
Comparison of Bypass and Endovascular Intervention for Popliteal Occlusion with the Involvement of Trifurcation for Critical Limb Ischemia. 61
31536796 2020
17
Endovascular Revascularization Incorporating Infrapopliteal Coronary Drug-Eluting Stents Improves Clinical Outcomes in Patients with Critical Limb Ischemia and Tissue Loss. 61
31563654 2020
18
Association Between Critical Limb Ischemia, the Society for Vascular Surgery Wound, Ischemia and Foot Infection (WIfI) Classification System and Arterial Stiffness. 61
31626931 2020
19
Quality of Life and Traditional Outcome Results at 1 Year in Elderly Patients Having Critical Limb Ischemia and the Role of Conservative Treatment. 61
31709914 2020
20
Electroacupuncture Attenuates Limb Ischemia-Reperfusion-Induced Lung Injury Via p38 Mitogen-Activated Protein Kinase-Nuclear Factor Erythroid-2-Related Factor-2/Heme Oxygenase Pathway. 61
31590030 2020
21
Distal Embolic Protection in Impella 5.0 Explantation: Loop and Snare Technique. 61
31563488 2020
22
Prognostic Factors for Survival After Extracorporeal Membrane Oxygenation for Cardiogenic Shock. 61
30864968 2020
23
Urgent Mechanical Thrombectomy by Indigo System® in Acute Thrombosed Popliteal Artery Aneurysms: A Report of Two Cases. 61
31648033 2020
24
Risk of Death and Amputation with Use of Paclitaxel-Coated Balloons in the Infrapopliteal Arteries for Treatment of Critical Limb Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 61
31954604 2020
25
Emergency Endovascular Treatment of Coral Reef Aorta with an Unconventional Technique. 61
31622762 2020
26
Complementary Impact of Carotid Intima-Media Thickness With Plaque in Associations With Noncardiac Arterial Vascular Events. 61
31303025 2020
27
Remote Ischemic Preconditioning Ameliorates Renal Fibrosis After Ischemia-Reperfusion Injury via Transforming Growth Factor beta1 (TGF-β1) Signalling Pathway in Rats. 61
32024811 2020
28
Extracorporeal Membrane Oxygenation after Heart Transplantation: Impact of Type of Cannulation. 61
32035427 2020
29
Direct Cannulation in Minimally Invasive Cardiac Surgery With Limited Resources. 61
31336068 2020
30
Simultaneous Superficial Femoral Artery Angioplasty/Stent Plus Popliteal Distal Bypass for Limb Salvage. 61
31669474 2020
31
Midterm Results of Endovascular Treatment for Complete Iliac Axis Occlusions Using Covered Stents. 61
31626933 2020
32
Retinal microvascular findings and risk of incident peripheral artery disease: An analysis from the Atherosclerosis Risk in Communities (ARIC) Study. 61
31812251 2020
33
Trends in statin utilization among adults with severe peripheral artery disease including critical limb ischemia in an integrated healthcare delivery system. 61
31512991 2020
34
High fat diet pre-conditioning improves microvascular remodeling during regeneration of ischemic mouse skeletal muscle. 61
32012450 2020
35
Pseudoaneurysm of Patent Ductus Arteriosus Following Previous PDA Closure: Case Report and Literature Review. 61
31707973 2020
36
Extracellular Vesicles From Adipose Stem Cells Prevent Muscle Damage and Inflammation in a Mouse Model of Hind Limb Ischemia: Role of Neuregulin-1. 61
31665908 2020
37
Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: A systematic review and meta-analysis. 61
31964311 2020
38
Approach to Tibiopedal Retrograde Revascularization of Below-The-Knee Peripheral Arterial Diseases With or Without Transradial Guidance Peripheral Angiography. 61
31893502 2020
39
A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause. 61
31951936 2020
40
Noncoding RNAs in Critical Limb Ischemia. 61
31893949 2020
41
Outcomes of severe limb ischemia with tissue loss and impact of revascularization in haemodialysis patients with wound, ischemia, and foot infection (WIfI) stage 3 or 4. 61
31483747 2020
42
Real-World Outcomes of EKOS Ultrasound-Enhanced Catheter-Directed Thrombolysis for Acute Limb Ischemia. 61
31917220 2020
43
Kissing Balloon Technique for Infrapopliteal Angioplasty in Patients with Critical Limb Ischemia. 61
31918037 2020
44
The Effect of Acute Limb Ischemia on Mortality in Patients Undergoing Femoral Venoarterial Extracorporeal Membrane Oxygenation. 61
31449945 2020
45
Acute Upper Limb Ischemia Due to Delayed Presentation of a Brachial Artery Pseudoaneurysm Post-Venipuncture. 61
31533547 2020
46
Efficacy of intra-arterial catheter-directed thrombolysis for popliteal and infrapopliteal acute limb ischemia. 61
31327613 2020
47
Single-center experience with Indigo aspiration thrombectomy for acute lower limb ischemia. 61
31918998 2020
48
Endovascular Versus Surgical Revascularization for Acute Limb Ischemia: A Propensity-Score Matched Analysis. 61
31948292 2020
49
Evaluation of skeletal muscle perfusion in a canine hind limb ischemia model using CT perfusion imaging. 61
31650969 2020
50
The Clinical Outcomes in Patients with Critical Limb Ischemia One Year after Spinal Cord Stimulation. 61
30802587 2020

Variations for Limb Ischemia

Expression for Limb Ischemia

Search GEO for disease gene expression data for Limb Ischemia.

Pathways for Limb Ischemia

Pathways related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.23 VWF VEGFA TNF TEK PGF NOS3
2
Show member pathways
14.09 VWF VEGFA TNF TEK SIGLEC5 NOS3
3
Show member pathways
13.89 VEGFA TNF TEK PGF KDR IL6
4
Show member pathways
13.75 VEGFA TEK PGF NOS3 MMP9 KDR
5
Show member pathways
13.74 TNF TEK NOS3 KDR IL6 HGF
6
Show member pathways
13.61 TEK PGF NOS3 KDR IL6 HGF
7
Show member pathways
13.61 VEGFA TNF TEK PGF KDR IL6
8
Show member pathways
13.55 VWF VEGFA TNF TEK MMP9 KDR
9
Show member pathways
13.45 TNF TEK PGF NOS3 KDR IL6
10
Show member pathways
13.43 VWF VEGFA TNF TEK MMP9 IL6
11
Show member pathways
13.38 TEK PGF KDR IL6 HGF FGF2
12
Show member pathways
13.36 VWF VEGFA TEK SELE NOS3 HGF
13
Show member pathways
13.36 TNF TEK PGF KDR IL6 HGF
14
Show member pathways
13.33 VEGFA TNF TEK PGF NOS3 KDR
15
Show member pathways
13.11 PGF KDR IL6 HGF FGF2 CXCL12
16
Show member pathways
13.11 PGF KDR IL6 HIF1A HGF FGF2
17
Show member pathways
13.02 VEGFA TNF SELE MMP9 KDR IL6
18
Show member pathways
13.01 VEGFA TNF IL6 HIF1A FGF2 CXCL12
19
Show member pathways
12.94 VWF VEGFA TNF TEK PGF NOS3
20 12.87 VEGFA PGF MMP9 IL6 HIF1A HGF
21
Show member pathways
12.84 VEGFA TEK PGF KDR HGF FGF2
22 12.82 VEGFA TNF TEK PGF KDR HGF
23
Show member pathways
12.8 TNF PGF KDR IL6 HGF FGF2
24
Show member pathways
12.74 VEGFA NOS3 MMP9 KDR CXCL12 CCL2
25
Show member pathways
12.7 VEGFA KDR IL6 HIF1A HGF FGF2
26
Show member pathways
12.68 TNF TEK NOS3 IL6 FGF2 CCL2
27
Show member pathways
12.5 TEK PGF KDR IL6 HGF FGF2
28
Show member pathways
12.47 VEGFA SELE NOS3 KDR CCL2
29
Show member pathways
12.38 TNF MMP9 IL6 CCL2
30
Show member pathways
12.38 TNF IL6 CXCL12 CCL2
31
Show member pathways
12.36 TNF PGF KDR IL6 HGF FGF2
32 12.36 VEGFA TNF MMP9 KDR HIF1A HGF
33
Show member pathways
12.3 TNF IL6 EDN1 ACE
34
Show member pathways
12.29 VEGFA NOS3 KDR FGF2
35 12.24 VEGFA TNF MMP9 IL6
36 12.23 VEGFA TNF IL6 HIF1A
37 12.19 TEK KDR FGF2 ANGPT2
38 12.18 VEGFA KDR IL6 HGF FGF2
39 12.09 TNF MMP9 IL6 CCL2
40 12.07 VEGFA TNF SELE NOS3 MMP9 KDR
41 12.05 TNF SELE MMP9 IL6 EDN1 CCL2
42 12.01 VEGFA TEK NOS3 IL6 HIF1A EDN1
43
Show member pathways
11.97 VEGFA PGF NOS3 KDR HIF1A
44 11.95 VEGFA TNF SELE NOS3 IL6 EDN1
45 11.92 VEGFA TNF TEK IL6 CXCL12 CCL2
46 11.83 TNF MMP9 IL6 CCL2
47 11.81 VEGFA TNF MMP9 IL6 HIF1A HGF
48 11.8 PGF IL6 HGF FGF2 CXCL12
49 11.78 VEGFA HIF1A EDN1 CXCL12
50
Show member pathways
11.76 VEGFA TNF SELE MMP9 IL6

GO Terms for Limb Ischemia

Cellular components related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.87 NOS3 IL6 HIF1A FGF2 EDN1 CXCL12
2 extracellular space GO:0005615 9.77 VEGFA TNF SELE PGF MMP9 IL6
3 membrane raft GO:0045121 9.67 TNF TEK SELE KDR
4 extracellular region GO:0005576 9.5 VWF VEGFA TNF TEK PGF MMP9
5 platelet alpha granule lumen GO:0031093 9.43 VWF VEGFA HGF
6 Weibel-Palade body GO:0033093 9.16 VWF EDN1

Biological processes related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.33 VEGFA TEK PGF IL6 HIF1A FGF2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 VEGFA TNF IL6 HIF1A HGF FGF2
3 positive regulation of gene expression GO:0010628 10.11 VEGFA TNF NOS3 IL6 HIF1A
4 negative regulation of apoptotic process GO:0043066 10.1 VEGFA TEK MMP9 KDR IL6 HIF1A
5 positive regulation of cell proliferation GO:0008284 10.09 VEGFA PGF KDR IL6 FGF2 EDN1
6 MAPK cascade GO:0000165 10.03 TNF TEK HGF FGF2 CCL2
7 extracellular matrix organization GO:0030198 10.02 VWF TNF MMP9 KDR FGF2
8 leukocyte migration GO:0050900 10.01 TNF TEK SELE ANGPT2
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 TNF TEK KDR FGF2 CCL2
10 positive regulation of protein kinase B signaling GO:0051897 9.99 TNF TEK HGF FGF2
11 negative regulation of gene expression GO:0010629 9.97 VEGFA TNF KDR HIF1A EDN1 ACE
12 positive regulation of cell migration GO:0030335 9.93 VEGFA MMP9 KDR HGF EDN1 CXCL12
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.91 TNF TEK KDR HGF
14 positive regulation of protein phosphorylation GO:0001934 9.91 VEGFA TNF TEK PGF MMP9 KDR
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 VEGFA TNF IL6
16 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.89 VEGFA PGF KDR
17 regulation of blood pressure GO:0008217 9.88 NOS3 EDN1 ACE
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 TNF IL6 EDN1
19 humoral immune response GO:0006959 9.87 TNF IL6 CCL2
20 positive regulation of MAP kinase activity GO:0043406 9.87 VEGFA TNF FGF2 EDN1
21 response to hypoxia GO:0001666 9.87 VEGFA TEK PGF HIF1A EDN1 CXCL12
22 positive regulation of cell adhesion GO:0045785 9.86 VEGFA TNF CXCL12
23 cytokine-mediated signaling pathway GO:0019221 9.86 VEGFA TNF MMP9 IL6 HIF1A HGF
24 positive regulation of cell division GO:0051781 9.85 VEGFA PGF FGF2
25 negative regulation of blood vessel endothelial cell migration GO:0043537 9.84 MIR503 FGF2 ANGPT2
26 positive regulation of endothelial cell migration GO:0010595 9.84 VEGFA TEK KDR EDN1
27 protein kinase B signaling GO:0043491 9.83 TNF KDR CCL2
28 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.83 VEGFA KDR FGF2
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF NOS3 CCL2
30 positive chemotaxis GO:0050918 9.83 VEGFA PGF HGF FGF2
31 blood vessel morphogenesis GO:0048514 9.81 HIF1A EDN1 ANGPT2
32 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.81 TNF MMP9 FGF2 EDN1
33 positive regulation of focal adhesion assembly GO:0051894 9.8 VEGFA TEK KDR
34 positive regulation of blood vessel endothelial cell migration GO:0043536 9.8 VEGFA NOS3 KDR HIF1A FGF2
35 animal organ regeneration GO:0031100 9.78 PGF HGF CXCL12 ANGPT2
36 cell migration involved in sprouting angiogenesis GO:0002042 9.77 VEGFA KDR FGF2
37 positive regulation of chemokine production GO:0032722 9.77 TNF IL6 HIF1A
38 vascular endothelial growth factor signaling pathway GO:0038084 9.76 VEGFA PGF KDR
39 induction of positive chemotaxis GO:0050930 9.75 VEGFA PGF CXCL12
40 sprouting angiogenesis GO:0002040 9.73 VEGFA TEK PGF KDR
41 regulation of neuroinflammatory response GO:0150077 9.72 MMP9 IL6
42 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
43 positive regulation of receptor biosynthetic process GO:0010870 9.72 HIF1A EDN1
44 neutrophil mediated immunity GO:0002446 9.71 IL6 ACE
45 positive regulation of axon extension involved in axon guidance GO:0048842 9.7 VEGFA CXCL12
46 positive regulation of endothelial cell proliferation GO:0001938 9.7 VEGFA TEK PGF KDR HIF1A FGF2
47 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.69 VEGFA HIF1A
48 positive regulation of mast cell chemotaxis GO:0060754 9.69 VEGFA PGF
49 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.69 NOS3 EDN1
50 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.68 VEGFA KDR

Molecular functions related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 VWF VEGFA TNF TEK SIGLEC5 SELE
2 integrin binding GO:0005178 9.56 VWF KDR FGF2 CXCL12
3 chemoattractant activity GO:0042056 9.46 VEGFA PGF HGF FGF2
4 growth factor activity GO:0008083 9.43 VEGFA PGF IL6 HGF FGF2 CXCL12
5 vascular endothelial growth factor receptor binding GO:0005172 9.37 VEGFA PGF
6 cytokine activity GO:0005125 9.17 VEGFA TNF IL6 FGF2 EDN1 CXCL12

Sources for Limb Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....